Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SI-B003 alone and BL-B01D1 + SI-B003 in advanced or metastatic urothelial and other genitourinary solid tumors
CTR20232346Phase 2Active
- Sponsor
- Biokin Pharmaceutical
- Start
- Aug 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of SI-B003, izalontamab brengitecan in transitional cell carcinoma (TCC), renal cell carcinoma (RCC), prostate cancer (PCa), genitourinary cancer, Nonhematologic neoplasms, sponsored by Biokin Pharmaceutical. Started Aug 2023; status: active.
02
Drugs
SI-B003izalontamab brengitecan
03
Conditions
transitional cell carcinoma (TCC)renal cell carcinoma (RCC)prostate cancer (PCa)genitourinary cancerNonhematologic neoplasms
Beyond the preview
Go deeper on CTR20232346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232346.